Skip to main content

Table 1 Effect of Ni-NTA chelating lipids on the efficiency of loading for various anticancer drugs into liposomes.

From: A novel assay for monitoring internalization of nanocarrier coupled antibodies

Chelating lipid

Drug loaded1

Drug-to-lipid2 ratio – input (μg/μmol)

Drug-to-lipid3 ratio – final (μg/μmol)

Loading4 efficiency (%)

none

DOX

150

159.4 ± 6.1

106.3 ± 14.4

Ni-NTA-DOGS

DOX

150

40.4 ± 4.3

26.9 ± 3.0

Ni-NTA-PEG-DSPE

DOX

150

138.2 ± 10.2

92.2 ± 8.0

none

VRB

150

150.2 ± 4.9

100.2 ± 3.4

Ni-NTA-DOGS

VRB

150

13.6 ± 1.2

9.0 ± 0.9

Ni-NTA-PEG-DSPE

VRB

150

149.6 ± 5.8

99.8 ± 4.0

none

MTX

508

146.0 ± 20.3

28.7 ± 4.0

Ni-NTA-DOGS

MTX

508

149.8 ± 6.6

29.5 ± 1.3

Ni-NTA-PEG-DSPE

MTX

508

151.1 ± 7.2

29.7 ± 2.0

  1. 1Doxorubicin (DOX), vinorelbine (VRB), and methotrexate (MTX) were quantitated by absorbance at 498, 270, and 350 nm, respectively, following dissolution of the liposome sample in acid isopropanol.
  2. 2Phospholipid was determined by phosphate analysis as described by Bartlett, 1959
  3. 3Free drug was removed by Sephadex G-75 gel filtration chromatography.